Trials / Unknown
UnknownNCT03191539
Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate more objectively, through an imaging technique such as ultrasound, changes in joints and entheses of patients with active psoriatic arthritis (PAs) who will start treatment with Apremilast after the failure of other therapies such as synthetic DMARD (metrotrexato , Leflunomide ...). The hypothesis of the study is that the technique of ultrasound can demonstrate the efficacy of Apremilast in the treatment of patients with active PAs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | 30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation |
Timeline
- Start date
- 2017-11-02
- Primary completion
- 2019-06-14
- Completion
- 2019-06-14
- First posted
- 2017-06-19
- Last updated
- 2017-10-17
Source: ClinicalTrials.gov record NCT03191539. Inclusion in this directory is not an endorsement.